Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “EGFR-Mutant Lung Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Looking for participantsNCT05642572
What this trial is testing

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

Who this might be right for
Recurrent Lung Non-Small Cell CarcinomaStage IV Lung Cancer AJCC v8
SWOG Cancer Research Network 66
Not applicableActive Not RecruitingNCT07491211
What this trial is testing

Osimertinib Combined With Intracranial SRT for EGFR-Mutant NSCLC With Symptomatic Brain Metastases

Who this might be right for
NSCLC (Advanced Non-small Cell Lung Cancer)Brain Metastases From Non-small Cell Lung Cancer (NSCLC)Osimertinib+1 more
Fudan University 300
Testing effectiveness (Phase 2)Study completedNCT02155465
What this trial is testing

Trial of Ruxolitinib and Erlotinib in Patients With EGFR-mutant Lung Adenocarcinoma With Acquired Resistance to Erlotinib

Who this might be right for
Lung Cancer
Memorial Sloan Kettering Cancer Center 22
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06688656
What this trial is testing

Neoadjuvant Chemotherapy Sequentially Combined with Sintilimab in Resectable EGFR-Mutant NSCLC

Who this might be right for
Lung Cancer
Shanghai Chest Hospital 30
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07298148
What this trial is testing

Firmonertinib 160 mg in Patients With EGFR-Mutant Advanced NSCLC Demonstrating SD After 8 Week Induction With Firmonertinib 80 mg

Who this might be right for
NSCLC Stage IVEGFR Positive Non-small Cell Lung CancerEGFR-TKI Sensitizing Mutation
Peking University Cancer Hospital & Institute 28
Early research (Phase 1)Ended earlyNCT03599518
What this trial is testing

DS-1205c With Gefitinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer

Who this might be right for
Non Small Cell Lung Cancer
Daiichi Sankyo Co., Ltd. 20
Testing effectiveness (Phase 2)Active Not RecruitingNCT04545710
What this trial is testing

Osimertinib and Abemaciclib in EGFR Mutant Non-Small Cell Lung Cancer After Osimertinib Resistance

Who this might be right for
Lung Cancer
University of California, San Diego 18
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06585644
What this trial is testing

A Clinical Trial of Furmonertinib Combination Therapy As Neoadjuvant Treatment in Resectable EGFR-Mutated NSCLC

Who this might be right for
Lung Cancer (NSCLC)
Shanghai Pulmonary Hospital, Shanghai, China 44
Testing effectiveness (Phase 2)UnknownNCT02771314
What this trial is testing

Liquid Biopsy as a Tool to Evaluate Resistance to First and Third (AZD9291) (EGFR) (TKIs) in (EGFR) Mutant NSCLC

Who this might be right for
Non Small Cell Lung Cancer
Hellenic Oncology Research Group 48
Post-approval studies (Phase 4)Ended earlyNCT02299765
What this trial is testing

Intercalating and Maintenance Gefitinib in Combination With Chemotherapy for Advanced EGFR-mutant NSCLC

Who this might be right for
Non-small Cell Lung Cancer MetastaticEGFR Activating Mutation
Sichuan University 61
Not applicableUnknownNCT05377788
What this trial is testing

Lazertinib Real-world Observational Study of in Pre-treated EGFR T790M Mutant With Advanced Non-small Cell Lung Cancer

Who this might be right for
Metastatic Lung Non-Small Cell CarcinomaEGFR T790M
Samsung Medical Center 900
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07507188
What this trial is testing

Collaborative Clinical-translational Cohort of Amivantamab Plus Lazertinib and Amivantamab Plus Chemotherapy in Patients With EGFR-mutant, Locally Advanced or Metastatic/Recurrent Non-Small Cell Lung Cancer (INSTAR Study)

Who this might be right for
Non Small Cell Lung Cancer
Yonsei University 80
Testing effectiveness (Phase 2)UnknownNCT04829019
What this trial is testing

Neurocognition in NSCLC Patients Treated With Osimertinib or Osimertinib + WBI

Who this might be right for
Neurocognitive
Sun Yat-sen University 88
Testing effectiveness (Phase 2)Looking for participantsNCT07637448
What this trial is testing

EGFR-TKIs Plus PD-1 in EGFR-Mutant Advanced NSCLC

Who this might be right for
Lung Cancer Non-Small Cell Cancer (NSCLC)EGFR Activating MutationPD-1 Antibody
Nanfang Hospital, Southern Medical University 32
Testing effectiveness (Phase 2)Active Not RecruitingNCT05920135
What this trial is testing

First-in-Human Study of BBT-207 in Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutation After Treatment With EGFR TKI

Who this might be right for
EGFR Mutant Advanced Non-Small Cell Lung Cancer
Bridge Biotherapeutics, Inc. 24
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07001995
What this trial is testing

Limertinib Plus Carboplatin and Etoposide for EGFR-mutant NSCLC With SCLC Transformation After EGFR-TKI Progression

Who this might be right for
Small Cell Lung CancerNon Small Cell Lung CancerNon Small Cell Lung Cancer NSCLC
Hunan Province Tumor Hospital 30
Testing effectiveness (Phase 2)WithdrawnNCT05045404
What this trial is testing

Poziotinib and Ramucirumab for the Treatment of EGFR Exon 20 Mutant Stage IV Non-small Cell Lung Cancer

Who this might be right for
Metastatic Lung Non-Small Cell CarcinomaStage IV Lung Cancer AJCC v8Stage IVA Lung Cancer AJCC v8+1 more
M.D. Anderson Cancer Center
Large-scale testing (Phase 3)Active Not RecruitingNCT05184712
What this trial is testing

Phase 3 Clinical Study of AK112 for NSCLC Patients

Who this might be right for
Non-Squamous Non-small Cell Lung Cancer
Akeso 322
Testing effectiveness (Phase 2)UnknownNCT02655536
What this trial is testing

Bevacizumab and Erlotinib in Lung Cancer With Brain Metastases, a Phase II Trial

Who this might be right for
Carcinoma, Non-Small-Cell LungBrain Neoplasms
National Taiwan University Hospital 109
Testing effectiveness (Phase 2)UnknownNCT03647956
What this trial is testing

Atezolizumab in Combination With Bevacizumab, Carboplatin and Pemetrexed for EGFR-mutant Metastatic NSCLC Patients After Failure of EGFR Tyrosine Kinase Inhibitors

Who this might be right for
NSCLC Stage IIIBNSCLC Stage IVEGFR Activating Mutation
The University of Hong Kong 40
Next Page